Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Megison

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|September 1, 2012
Cell survival signaling in neuroblastomaMichael L Megison, Lauren A Gillory, Elizabeth A Beierle
Clinical & Experimental Metastasis|December 5, 2012
FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastomaMichael L Megison, Jerry E Stewart, Hugh C Nabers, et al.
The Journal of Surgical Research|April 12, 2015
Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survivalLauren A Gillory, Jerry E Stewart, Michael L Megison, et al.
Translational Oncology|April 2, 2013
FAK Inhibition Decreases Hepatoblastoma Survival Both In Vitro and In VivoLauren A Gillory, Jerry E Stewart, Michael L Megison, et al.
Molecular Cancer Research : MCR|January 28, 2014
FAK inhibition abrogates the malignant phenotype in aggressive pediatric renal tumorsMichael L Megison, Lauren A Gillory, Jerry E Stewart, et al.
Journal of Pediatric Surgery|June 19, 2012
Laparoscopic surgery in children with congenital heart diseaseLauren A Gillory, Michael L Megison, Carroll M Harmon, et al.
Plos One|February 6, 2014
Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumorsMichael L Megison, Lauren A Gillory, Jerry E Stewart, et al.
Plos One|October 17, 2013
Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastomaLauren A Gillory, Michael L Megison, Jerry E Stewart, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Anti-Cancer Agents in Medicinal Chemistry|September 1, 2012
Cell survival signaling in neuroblastomaMichael L Megison, Lauren A Gillory, Elizabeth A Beierle
Clinical & Experimental Metastasis|December 5, 2012
FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastomaMichael L Megison, Jerry E Stewart, Hugh C Nabers, et al.
The Journal of Surgical Research|April 12, 2015
Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survivalLauren A Gillory, Jerry E Stewart, Michael L Megison, et al.
Translational Oncology|April 2, 2013
FAK Inhibition Decreases Hepatoblastoma Survival Both In Vitro and In VivoLauren A Gillory, Jerry E Stewart, Michael L Megison, et al.
Molecular Cancer Research : MCR|January 28, 2014
FAK inhibition abrogates the malignant phenotype in aggressive pediatric renal tumorsMichael L Megison, Lauren A Gillory, Jerry E Stewart, et al.
Journal of Pediatric Surgery|June 19, 2012
Laparoscopic surgery in children with congenital heart diseaseLauren A Gillory, Michael L Megison, Carroll M Harmon, et al.
Plos One|February 6, 2014
Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumorsMichael L Megison, Lauren A Gillory, Jerry E Stewart, et al.
Plos One|October 17, 2013
Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastomaLauren A Gillory, Michael L Megison, Jerry E Stewart, et al.
Pageof 1